What is PACAP?
PACAP stands for pituitary adenylate cyclase-activating polypeptide, a naturally occurring neuropeptide involved in signalling throughout the nervous, endocrine and cardiovascular systems. It belongs to the same broader peptide family as vasoactive intestinal peptide (VIP).
PACAP exists primarily in two biologically active forms, PACAP-38 and PACAP-27. Research has established roles for endogenous PACAP in neural and endocrine signalling, while experimental research has investigated its involvement in migraine, cellular stress, inflammation and neuroprotection.
Pituitary adenylate cyclase-activating polypeptide
PACAP was originally identified during research seeking hypothalamic factors capable of stimulating adenylate cyclase activity in pituitary cells. Its name reflects this discovery rather than describing the full range of its physiological functions.
PACAP is now known to be widely distributed throughout the central and peripheral nervous systems and several peripheral organs. It acts as a neurotransmitter, neuromodulator and neuroendocrine signalling molecule.
Many PACAP-mediated effects involve increases in intracellular cyclic AMP (cAMP), although additional intracellular signalling pathways can also be activated depending on the receptor and cell type involved.
PACAP-27 and PACAP-38
PACAP occurs naturally in two principal forms: PACAP-38, containing 38 amino acids, and PACAP-27, containing 27 amino acids.
PACAP-38 is generally considered the predominant form in mammalian tissues. PACAP-27 corresponds to the first 27 amino acids of PACAP-38 and retains substantial biological activity.
The two peptides interact with the same major receptor systems but can differ in distribution, stability and pharmacological behaviour. Scientific studies should therefore identify which form of PACAP was investigated.
PAC1 receptor
PAC1 is a G-protein-coupled receptor with particularly high affinity for PACAP. It is encoded by the ADCYAP1R1 gene and is expressed in numerous regions of the nervous system and peripheral tissues.
Activation of PAC1 can influence intracellular signalling pathways involving cAMP, calcium and other second-messenger systems. Multiple PAC1 receptor variants produced through alternative splicing add further complexity to PACAP signalling.
PACAP also activates VPAC1 and VPAC2 receptors, which are shared with VIP. Its comparatively strong activity at PAC1 is one of the major pharmacological characteristics distinguishing PACAP from VIP.
Relationship to VIP
PACAP and VIP are closely related members of the secretin/glucagon peptide family. Their amino-acid sequences share substantial similarity, particularly between PACAP-27 and VIP.
Both peptides activate VPAC1 and VPAC2 receptors. However, PACAP additionally displays high affinity for PAC1, whereas VIP has substantially weaker activity at this receptor.
This overlapping but distinct receptor pharmacology explains why PACAP and VIP can produce similar effects in some biological systems while behaving differently in others.
Neurological signalling
PACAP is widely expressed throughout the brain and peripheral nervous system. Research has identified roles in neuronal communication, autonomic regulation, stress responses, sensory processing and neuroendocrine signalling.
PACAP and PAC1 receptors are present in brain regions involved in processes including emotion, pain, circadian regulation and responses to physiological stress.
Because the PACAP system participates in numerous neural pathways, an effect observed in one experimental model should not automatically be generalised to overall neurological function.
Migraine research
Migraine has become one of the most prominent areas of human PACAP research. Experimental administration of PACAP has been shown to provoke migraine-like attacks in susceptible participants, providing evidence that PACAP signalling can participate in migraine biology.
Researchers have consequently investigated PACAP itself and its receptors as potential molecular targets for migraine therapies.
PACAP-related migraine signalling overlaps with, but is not identical to, the extensively studied calcitonin gene-related peptide (CGRP) system. Understanding the relationship between these pathways remains an active area of headache research.
Neuroprotection research
Cellular and animal studies have investigated PACAP in models involving neuronal injury, oxidative stress, inflammation and other forms of cellular damage.
Experimental findings have suggested that PACAP signalling can influence pathways involved in neuronal survival and stress responses. These observations have generated interest in potential neuroprotective mechanisms involving PAC1 and related signalling pathways.
However, neuroprotection demonstrated in cultured cells or animal models does not establish that externally supplied PACAP prevents or treats neurological disease in humans.
Endocrine biology
PACAP was discovered through its effects on pituitary signalling, and neuroendocrine biology remains an important component of its physiology.
The peptide is present within hypothalamic and pituitary-related pathways and has been investigated for interactions with hormone secretion and physiological stress responses. PACAP signalling is also involved in communication between the nervous system and several endocrine organs.
These interactions illustrate why PACAP cannot be understood solely as a neurological peptide. It participates in broader communication between neural, endocrine and peripheral physiological systems.
PACAP vs VIP
PACAP and VIP are closely related but distinct endogenous peptides.
PACAP occurs predominantly as PACAP-38, with PACAP-27 representing a shorter naturally occurring form. VIP consists of 28 amino acids.
Both activate VPAC1 and VPAC2 receptors, but PACAP's high affinity for PAC1 provides an important distinction. PACAP has received substantial attention in neurobiology and migraine research, whereas VIP has particularly well-established roles in gastrointestinal, vascular and autonomic physiology.
Their overlapping receptor activity means their biology intersects, but experimental findings involving one peptide should not automatically be attributed to the other.
Human research
PACAP has been studied directly in humans, particularly within migraine and vascular research. Experimental studies demonstrating migraine-like attacks following PACAP exposure have provided important evidence connecting the signalling pathway with human headache biology.
Human observational studies have also examined endogenous PACAP concentrations and signalling in different physiological and disease contexts.
However, evidence that endogenous PACAP participates in a biological process is different from evidence that administering PACAP provides a therapeutic benefit. Human claims must therefore be tied to the exact experimental intervention and endpoint studied.
Frequently asked questions
What does PACAP stand for?
PACAP stands for pituitary adenylate cyclase-activating polypeptide.
Is PACAP naturally produced by humans?
Yes. PACAP is an endogenous neuropeptide found throughout the nervous system and several peripheral tissues.
What are PACAP-38 and PACAP-27?
They are the two principal naturally occurring forms of PACAP, containing 38 and 27 amino acids respectively. PACAP-38 is generally the predominant form.
What is the PAC1 receptor?
PAC1 is a G-protein-coupled receptor with high affinity for PACAP. It participates in several neural, endocrine and cellular signalling pathways.
Is PACAP the same as VIP?
No. They are closely related peptides and share VPAC1 and VPAC2 receptors, but PACAP additionally has strong activity at the PAC1 receptor.
Why is PACAP important in migraine research?
Human experimental studies have demonstrated that PACAP can provoke migraine-like attacks in susceptible individuals, supporting investigation of the PACAP signalling pathway in migraine biology.
Does neuroprotection research prove PACAP can treat neurological disease?
No. Neuroprotective effects observed in cellular or animal experiments do not establish therapeutic effectiveness in humans.
Scientific references
Scientific literature on PACAP includes research into its original discovery, PACAP-27 and PACAP-38, PAC1/VPAC receptor pharmacology, neuroendocrine signalling, migraine biology and experimental neuroprotection. Evidence should be evaluated according to the specific PACAP form, receptor, experimental model and endpoint investigated, with cellular and animal findings clearly distinguished from direct human evidence.